Precisely one year after a hoped-for strategic partnering deal fell through, Somatix Therapy Corp. has signed its first corporate deal, with Baxter Healthcare Corp., to develop a gene therapy approach for hemophilia.
Under the agreement, SOMA will develop a cell line that produces factor VIII or factor IX, and will use its MFG retroviral vector to insert the gene for factor VIII or IX into a non-autologous human cell line. Baxter will be responsible for the insertion of the cells into a membrane device it has developed and for clinical trials and marketing.
SOMA will receive milestones and royalties. Baxter also has a right